Ask Questions, Get Answers
With the recent discovery of HPV carcinogenic strains being found in oral pharyngeal tumor genetic PCR studies and a flurry of back date specimen screening finding 40-50% positive for HPV so far with 70% positives correlating to carcinogenic strains from Gynecologic standards, 1-do you believe the Gardasil vaccine's dual dosing will elicit protection pharyngeally for future exposures for naive patients as the researchers propose? 2-Do you think the exhorbitant cost of 6-700.00 per dose can be brought down to affordable means for the tens of millions of age introduction riskees or that the Federal gov't may subsidize this to 20-50.00 as for other childhood vaccines, 3- What about the estimated 50 million plus inductees to exposure after the scandalous 90's US cultural epidemic of oral sexual experimenting between 1995 and 2007 aided in expansion thru presidential exhibitionism and exploitive validation; do you think oral pharyngeal PAPs/PCRs will suffice? This is real.
>When answered, perhaps input by someone with ENT or diagnostic oncology, pathology or vaccine development would be best.This is a critically important issue for the future younger Male and Female generation populations of American patients and holds great concern to the same degree as Breast Ca, Prostate Ca, PAP smear, HepC and Aids screening in Epidemiologic cost and consequence of changing cultural behaviors, responsible sexuality and Health Prevention awareness. Remember, in screening surveys of the 1990s 43% of sexually active females aged 18-35 in FL college communities were found to harbor HPV without knowledge or tissue changes. This bodes great omenence and did not include the expansion for ages 11-18 unfolding after 1995 involved in fad experimenting, thus these classes still exist, regenerating at age 11-13 on up to the past population who are now 12 years older; and no males of hetero or homosexual experience were studied, who seem to predominate in the pharyngeal tumor findings so far. Additional Details added 2 years ago
Perhaps a reviewer would benefit from obtaining the opinion of departments in NIH or the CDC(old term).This would be actual research effort, add to experience & knowledge & illustrate expertise on the horizon? Also the Armed Forces Institute of Pathology in Bethesda is best Pathology resource for innovative & obscure pathologiy & proferring of new ideas.Go beyond what is in immediate grasp.The answers are out there in proposition as well as partial solution, from epidemiology to screening to treatment & prevention & concern for public informing.They just aren't officially adopted,approved by formality or funded(BIG POINT).Your answer may do more for the US public health effort than the advent of commercially profitted Gardasil's political bribery,as charged in Texas, to be ramrodded in public scare to a frightened citizenry who want protection for their children in a morally declining adolescent world at any price,though they know not where the exhorbitant cost will be covered & as known with the HepBVax & VaricellaVax programs after dissemination, know not the effectiveness of the 'immunization take" rate for prescribed dosage series,as the subtle complication rate mounts with each big number expansion of introducing foreign immune proteins that tend,in all cases,to elicit overreaction to some percentage to be reached asymptotically as numbers increase.(You may not know of the secret gov't fund for active induced Polio cases(~7/yr), but you should remember the consequences of the Swine Flu Vaccine. Added to the move to push Anthrax Vaccination & Beta tested HSV1 and 2 commercial products & you find a new amazing& dangerous world for angels to not dare tread.They wait,humbled,at the exit.to the upcoming political front of the presidential race. Don't take this blindly. Simply querie a Congressman.Federal attention to public health stirs once again. Whether it settles to the bottom again, or remains in the public view independently is yet to be determined.
Additional Details added 2 years ago
Safety and Adverse Events
The quadrivalent HPV vaccine was evaluated for injection-site and systemic adverse events, new medical conditions reported during the follow-up period, and safety during pregnancy and lactation. Safety data on quadrivalent HPV vaccine are available from seven clinical trials and include 11,778 persons aged 9--26 years who received quadrivalent vaccine and 9,686 who received placebo. Detailed data were collected using vaccination report cards for 14 days following each injection of study vaccine on a subset of participants aged 9--23 years. The population with detailed safety data included 5,088 females who received quadrivalent HPV vaccine and 3,790 who received placebo (Tables 7--9) (111). Local Adverse Events In the study population with detailed safety data, a larger proportion of persons reported injection-site adverse events in the group that received quadrivalent HPV vaccine compared with aluminum-containing or saline placebo groups (Table 7). Pain was the most common injection site adverse event, reported by 83.9% of vaccinees, 75.4% of those who received aluminum-containing placebo, and 48.6% of those who received saline placebo. Swelling and erythema were the next most common reactions in the vaccine and placebo groups. The majority of injection-site adverse experiences reported among recipients of quadrivalent HPV vaccine were mild to moderate in intensity; only 2.8%, 2.0%, and 0.9% of vaccinees reported severe pain, swelling, or erythema, respectively. Systemic Adverse Events Systemic clinical adverse events were reported by a similar proportion of vaccine and placebo recipients in the population with detailed safety data (Table 8). In both quadrivalent HPV vaccine and placebo groups, more persons reported a systemic clinical adverse experience in the 15 days after dose 1 compared with after dose 2 and after dose 3. For the majority of persons, the maximum intensity rating of systemic clinical adverse events Additional Details added 2 years ago
Systemic clinical adverse events were reported by a similar proportion of vaccine and placebo recipients in the population with detailed safety data (Table 8). In both quadrivalent HPV vaccine and placebo groups, more persons reported a systemic clinical adverse experience in the 15 days after dose 1 compared with after dose 2 and after dose 3. For the majority of persons, the maximum intensity rating of systemic clinical adverse events was mild or moderate. Overall, 4.0%--4.9% of females who received quadrivalent HPV vaccine reported a temperature of >100°F (>38°C) after dose one, two, or three (Table 9).
Serious Adverse Events in All Safety Studies Vaccine-related serious adverse events occurred in <0.1% of persons. The proportions of persons reporting a serious adverse event were similar in the vaccine and placebo groups, as were the types of serious adverse events reported. Seven persons had events that were determined to be possibly, probably, or definitely related to the vaccine or placebo. Five events occurred among quadrivalent HPV vaccine recipients and two among placebo recipients. The five in the quadrivalent HPV vaccine group included bronchospasm, gastroenteritis, headache/hypertension, vaginal hemorrhage, and injection site pain/movement impairment. In the overall safety evaluation, 10 persons in the group that received quadrivalent HPV vaccine and seven persons in the placebo group died during the course of the trials. None of the deaths was considered to be vaccine related. Two deaths in the vaccine group and one death in the placebo group occurred within 15 days following vaccination. Seven deaths were attributed to motor-vehicle accidents (four in vaccine group and three in placebo group), three were caused by intentional overdose (nonstudy medications) or suicide (one in vaccine group and two in placebo group), two were attributed to pulmonary embolus or deep venous thrombosis (one each in vaccine and placebo group), two were attri Additional Details added 2 years ago
TABLE 1. Cancers associated with human papillomavirus
(HPV) and percentage attributable —to oncogenic HPV United States, 2003 Cancer Cases %Attributable to oncogenic HPV Cervix 11,820 100 Anus 4,187 90 Vulva 3,507 40 Vagina 1,070 40 Penis 1,059 40 Oral cavity & pharynx 29,627 12 Source http://www.cdc,gov/uscs Additional Details added 2 years ago
Sorry for table malfunction:
2003 cancers asoc. with HPV & %attrib to oncogenic HPV (& number calc'd) (Only Gov't programs reporting-numbers really higher) Cervix 11,820 100 11,820 Anus 4,187 90 3,769 Vulva 3,507 40 1,403 Vagina 1,070 40 428 Penis 1,059 40 424 ORAL CAVITY&PHARYNX 29,627 12 3,556 My calc: 3556/21,400 = 16.6% all HPV cancers documented Remember, the at risk exposure population is in 10s of Millions for oral contact Additional Details added 2 years ago
Alternate opinion yield, at least 1 or 2 serious responses more, lots of views, hopefully at least one more to present to further authorities as example of public reaction.
Best Answer
Related Question Suggestions
|
Need Answers Instantly?
About this Question
Answered Question
Asked by Dareg
( )
Question Discussion
Top Users this Week
|
Comments
Loading...